[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100610104":3},{"organization":4,"armGroups":7,"interventions":29,"overallOfficials":33,"centralContacts":33,"locations":43,"responsibleParty":63,"collaborators":33,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":69,"sex":74,"minAge":75,"maxAge":33,"enrollmentInfo":76,"targetDuration":33,"studyType":79,"phases":80,"briefSummary":83,"conditions":84,"keywords":87,"overallStatus":45,"whyStopped":33,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"University of Texas Southwestern Medical Center","OTHER",[8,14,20,25],{"label":9,"type":10,"description":11,"interventionNames":12},"Moderate-intensity continuous training (MCT)","ACTIVE_COMPARATOR","Tailored moderate-intensity exercise training video with weekly virtual meetings with a coach",[13],"Behavioral: Moderate-intensity continuous training (MCT)",{"label":15,"type":16,"description":17,"interventionNames":18},"Moderate-intensity continuous training + weight loss","EXPERIMENTAL","Tailored moderate-intensity exercise training videos with weekly virtual meetings with a coach + initiation\u002Fintensification of pharmacological weight loss",[13,19],"Drug: Weight loss",{"label":21,"type":16,"description":22,"interventionNames":23},"Moderate-intensity continuous training + resistance training","Tailored moderate-intensity exercise training videos with weekly virtual meetings with a coach + tailored resistance training videos",[13,24],"Behavioral: Resistance training",{"label":26,"type":16,"description":27,"interventionNames":28},"Moderate-intensity continuous training + resistance training + weight loss","Tailored moderate-intensity exercise training videos with weekly virtual meetings with a coach + tailored resistance training videos + initiation\u002Fintensification of pharmacological weight loss",[13,24,19],[30,34,38],{"type":31,"name":9,"description":11,"armGroupLabels":32,"otherNames":33},"BEHAVIORAL",[9,21,26,15],null,{"type":31,"name":35,"description":36,"armGroupLabels":37,"otherNames":33},"Resistance training","Resistance training videos assigned to patient",[21,26],{"type":39,"name":40,"description":41,"armGroupLabels":42,"otherNames":33},"DRUG","Weight loss","Initiation\u002Fintensification of weight loss medications, such as semaglutide or tirzepatide",[26,15],[44],{"facility":5,"status":45,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"RECRUITING","Dallas","Texas","75209","United States","US",{"type":52,"coordinates":53},"Point",[54,55],-96.80667,32.78306,{"lat":55,"lon":54},[58],{"name":59,"role":60,"phone":61,"phoneExt":33,"email":62},"Ambarish Pandey, MD","CONTACT","214-645-9868","ambarish.pandey@utsouthwestern.edu",{"type":64,"investigatorFullName":65,"investigatorTitle":66,"investigatorAffiliation":5,"oldNameTitle":33,"oldOrganization":33},"PRINCIPAL_INVESTIGATOR","Ambarish Pandey","Associate Professor of Medicine","100610104","phase-2-tailored-exercise-training-study-among-adults-with-hfpef-100610104",false,"NCT07223242","Tailored Exercise Training Study Among Adults With HFpEF","TEXPEF","Inclusion Criteria:\n\n1. Age\\>= 18 yrs\n2. LVEF (Left Ventricular Ejection Fraction) \\>= 50%\n3. History of HFpEF or at risk of HFpEF\n\n   1. HFpEF diagnosis based on:- -HF hospitalization within 12 months-\n\n      * NT-proBNP \\>360 pg\u002FmL\n   2. Risk of HFpEF based on:-\n\n      * \\>2 risk factors (h\u002Fo diabetes, hypertension, obesity, physical inactivity by self-report)\n4. SPPB \\\u003C 10 or VO2\\\u003C60th percentile\n5. BMI \\>=28 (for randomization in phase II)\n6. Able to use cell phone and mobile application\n\nExclusion Criteria:\n\n1. Hospitalization 1 month prior to baseline visit\n2. History of recurrent falls\n3. eGFR (Estimated Glomerular Filtration Rate) \\\u003C20ml\u002Fmin\u002F1.73m\n4. Active changes in HF therapies over 2 weeks prior to baseline visit\n5. Inability participate in exercise training therapy\n6. Inability to perform CPET (Cardiopulmonary Exercise Testing) testing\n7. Severe left side valvular heart disease\n8. End stage pulmonary disease, requiring continuous supplemental oxygen\n9. Major surgery within 3 months of screening or major elective surgery during the duration of the study.\n10. Unstable weight defined by \\>5% change in body weight in last 30 days before first study visit.\n11. Pregnancy","ALL","18 Years",{"count":77,"type":78},120,"ESTIMATED","INTERVENTIONAL",[81,82],"PHASE2","PHASE3","Heart failure with preserved ejection fraction (HFpEF) is associated with a high morbidity and mortality burden. There are limited pharmacological options available for the treatment of HFpEF. Exercise intolerance (EI) is the cardinal symptom of HFpEF, which manifests as dyspnea and fatigue. EI leads to functional deconditioning and reduced quality of life (QOL), both of which elevate risk of death and hospitalization in patients with HFpEF. Supervised exercised training is associated with improvements in exercise capacity and QOL in adults with HFpEF. However, supervised exercise has not been widely utilized for the treatment of HFpEF due to logistical and fiscal barriers.\n\nThis study will investigate the effects of a remote exercise training intervention on exercise capacity and skeletal muscle composition in patients with HFpEF, or those at risk for it. In addition, it will compare four different lifestyle interventions for their effects on exercise capacity.",[85,86],"HFpEF - Heart Failure With Preserved Ejection Fraction","Diabetic Cardiomyopathies",[88,89,40,90],"Diabetic cardiomyopathy","Remote exercise training","Rehab","2025-10-28",{"date":93,"type":94},"2025-10-31","ACTUAL",{"date":96,"type":94},"2025-02-18",{"date":98,"type":78},"2026-12-30",{"name":5,"class":6},1]